Unresectable Dedifferentiated Liposarcoma
📧 Sign up to get email alerts when something new happens for Unresectable Dedifferentiated Liposarcoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas [Phase 3]
This Phase 3 trial is evaluating whether adding immunotherapy to chemotherapy improves outcomes versus chemotherapy alone in patients with a…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma [Phase 1, Phase 2]
This update reports on a Phase 1/2 clinical trial evaluating the MEK inhibitor mirdametinib in combination with palbociclib for liposarcoma,…
-
CLINICAL_TRIALS research · 2026-01-26Clinical Trial Update: Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma [Phase 2]
Phase 2 study evaluating cemiplimab in combination with palbociclib for advanced or unresectable dedifferentiated liposarcoma; the trial is …
-
CLINICAL_TRIALS trial_result · 2020-06-16Clinical Trial Update: Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery [Phase 2]
A Phase 2 trial evaluating nivolumab with or without ipilimumab in metastatic or unresectable sarcoma shows results from a completed study.